Details for Patent: 8,703,781
✉ Email this page to a colleague
Which drugs does patent 8,703,781 protect, and when does it expire?
Patent 8,703,781 protects TAFINLAR and MEKINIST and is included in four NDAs.
Protection for TAFINLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-five patent family members in thirty-two countries.
Summary for Patent: 8,703,781
| Title: | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
| Abstract: | A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-tr- ioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2- -fluorophen-}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer. |
| Inventor(s): | Dumble; Melissa (Collegeville, PA), Kumar; Rakesh (Collegeville, PA), Laquerre; Sylvie (Collegeville, PA), Lebowitz; Peter (Collegeville, PA) |
| Assignee: | GlaxoSmithKline LLC (Philadelphia, PA) |
| Application Number: | 13/499,779 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Device; Use; |
Drugs Protected by US Patent 8,703,781
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | 8,703,781*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-002 | May 29, 2013 | RX | Yes | Yes | 8,703,781*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | MEKINIST | trametinib dimethyl sulfoxide | SOLUTION;ORAL | 217513-001 | Mar 16, 2023 | RX | Yes | Yes | 8,703,781*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | TAFINLAR | dabrafenib mesylate | TABLET, FOR SUSPENSION;ORAL | 217514-001 | Mar 16, 2023 | RX | Yes | Yes | 8,703,781*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Novartis | MEKINIST | trametinib dimethyl sulfoxide | TABLET;ORAL | 204114-001 | May 29, 2013 | RX | Yes | No | 8,703,781*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,703,781
| PCT Information | |||
| PCT Filed | October 15, 2010 | PCT Application Number: | PCT/US2010/052808 |
| PCT Publication Date: | April 21, 2011 | PCT Publication Number: | WO2011/047238 |
International Family Members for US Patent 8,703,781
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010306653 | ⤷ Subscribe | |||
| Brazil | 112012008854 | ⤷ Subscribe | |||
| Canada | 2775803 | ⤷ Subscribe | |||
| Chile | 2012000964 | ⤷ Subscribe | |||
| China | 102655753 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
